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Background. Metabolic syndrome (MS) is characterised by a constellation of individual risk factors of cardiovascular disease.
Materials and Methods.The current study wasa population-based surveyofcohort of subjects inthe metropolitan cityof Mumbai.
A total of 548 subjects, who attended the CARDIAC evaluation camp, were recruited in the study. Participants with complete
fasting lipid proﬁles, blood glucose, and known cardiac risk markers were evaluated. Results. On applying modiﬁed NCEP ATP
III, we found out that nearly 95% of the subjects had at least one abnormal parameter. We found the prevalence of MS in our
study population to be 19.52%.The prevalence of MS in males was almostdouble thanfemales (P = .008).The overall prevalence
of BMI (>23kg/m2)w a s7 9 .01%. Increased hypertriglyceridemia and decreased levels of HDL-C were found to be more in males
(P<. 0001). Conclusion. The low percentage of subjects with normal and controlled parameters suggests that there is a need for
awareness programs and lifestyle interventions for the prevention and control of MS.
1.Introduction
A global transition in the disease pattern has been observed,
where the relative impact of infectious diseases is decreasing
while chronic diseases like cardiovascular disease (CVD) and
diabetes are increasingly dominating the disease pattern [1].
Epidemiologists in India and international agencies such as
the world health organization (WHO) have been sounding
an alarm on the rapidly rising burden of CVD for the past 15
years. It is estimated that by 2020, CVD will be the largest
cause of disability and death in India, with 2.6 million
Indians predicted to die due to CVD [2, 3].
The metabolic syndrome (MS) is a multiplex risk fac-
tor for atherosclerotic cardiovascular disease (ASCVD).
It consists of an atherogenic dyslipidemia ((i.e., elevated
triglycerides and apolipoprotein B (apo-B) and low high-
density lipoproteincholesterol (HDL-C)),elevationof blood
pressure and glucose, prothrombotic and proinﬂamma-
tory states. The risk of ASCVD accompanying the MS is
approximately doubled compared with an absence of the
syndrome. The MS appears to promote the development of
ASCVD at multiple levels. Elevations of apoB containing
lipoproteins initiate atherogenesis and drive lesion devel-
opment. Atherosclerotic plaque development is accelerated
by low levels of HDL-C, by elevated glucose levels and by
inﬂammatory cytokines [4, 5].
MS is a complex web of metabolic factors that are associ-
ated with a 2-fold risk of CVD and a 5-fold risk of diabetes.
Individuals with MS have a 30%–40% probability of devel-
oping diabetes and/or CVD within 20 years, depending on
the number of components present [6].
In the United States (US), the prevalence of the MS in
the adult population was estimated to be more than 25%.
Similarly, the prevalence of MS in 7 European countries was
approximately23%.Itwasestimatedthat20%–25%ofSouth
Asians have developed MS and many more may be prone to
it [7, 8]. The main reason why MS is attracting scientiﬁc and
commercial interest is that the factors deﬁning the syndrome2 Cholesterol
are all factors associated with increased morbidity and mor-
tality in general and from CVD in particular [1].
In this context, the aim of this study was to assess the
prevalenceofMSasdeﬁnedbyNCEPATPIIIguidelineswith
amodiﬁcation tothevalueforBMIthatismore applicableto
the Asian Indian population, and to look for the diﬀerences
between the various components constituting MS. Along
with the prevalence of MS, we also studied the prevalence of
various risk factors leading to ASCVD.
2.Materialsand Methods
2.1. Study Design. The current study was a population-
based survey of cohort in the metropolitan city of Mumbai
in Western India. Mumbai being the industrial capital of
India, the inhabitants here are heterogeneous both ethnically
and culturally. A total of 560 subjects, who attended the
free CARDIAC evaluation camp arranged by P. D. Hinduja
National Hospital and Medical Research Centre by general
advertising, were recruited in the study. Among the 560
subjects, 548 (302 males and 246 females) who had all the
required data for the analysis formed the study group.
Each participant was interviewed by a group of research
students and completed a standardized questionnaire con-
taining information on demographics, anthropometric pro-
ﬁle, individual characteristics associated with the major risk
factors of CVD, past medical history, and biochemical
parameters (Table 1). Prevalence of diabetes and hyperten-
sion was ascertained based on self-report of the physician’s
diagnosis and/or use of prescription medications along with
medical records of therapeutics. All participants gave their
written informed consent to participate in the study that was
approved by the local ethics committee.
2.2. Anthropometric Proﬁle. All measurements were carried
out by a group of research students. Body weight was deter-
mined with subjects wearing light clothes and no shoes or
socks, using an electronic balance. Height was determined
using a wall mounted, nonextendable measuring tape with
subjects in standing position and feet together. Body mass
index (BMI) was calculated using the expression:
BMI =
weight

kg

height
2 (m)
. (1)
2.3. Biochemical Analysis. Blood samples were collected by
venipuncture after an overnight fast for 12–14 hours.
Venous blood was collected in plain and ﬂuoride bulbs
for measurement of serum lipids, Lp(a), Apolipoproteins,
hsCRP, and glucose, respectively. The serum was separated
after centrifugation at 3000rpm for 10 minutes. The analysis
was carried on an automated clinical chemistry analyzer,
Beckman DXC 800. Serum glucose was measured by oxygen
ratemethodemployingaBeckmanoxygenelectrode(glucose
oxidase). Total cholesterol, triglyceride, and HDL-C concen-
trationwere measured by International Federationofclinical
chemistry (IFCC) approved enzymatic methods. Beckman
reagents and calibrators were used for the analysis. Control
Table 1: Study variablesfor the baseline survey of CVD riskfactors.
Study variables
Demographic Age
Gender
Behavioural Smoking
Alcohol consumption
Clinical examination Weight
Height
Questionnaire History of CVD, diabetes, HTN
Family history of CVD,
diabetes, HTN
Biochemical tests Fasting blood glucose
Total cholesterol (TC)
Triglyceride (TG)
HDL-C
APOA1, APOB. RATIO
Lp(a)
hsCRP
(HTN-hypertension, APO A1-apolipoprotein A1, Lp(a)-lipoprotein A,
hsCRP-High sensitive C-reactive protein).
sera were included in each batch of samples analyzed. hsCRP
detection is based on near infrared particle immunoassay
on DXC 800. Serum APO A1, APO-B, and Lp(a) were
determined by rate nephelometry on IMMAGE immuno-
chemistry system. It measures the rate of increase in light
scattered from particles suspended in solution as a result of
complexes formed during an antigen-antibody reaction. As a
part of external quality assurance, our laboratory is enrolled
with the proﬁciency testing surveys of college of American
pathologist (CAP) and is the 1st hospital laboratory in India
to be CAP accredited.
2.4. Deﬁnitions and Preferred CutoﬀValues. Forserumlipids,
we referred to National Cholesterol Education Program-
Adult Treatment Panel III (NCEP-ATP III) guidelines
[9]. According to these standard guidelines, hypercholes-
terolemiaisdeﬁnedasTC>200mg/dL,hypertriglyceridemia
as TG>150mg/dL, and low HDL-C as <40mg/dL. Dyslipi-
demia is deﬁned by presence of one or more than one abnor-
mal serum lipid concentration. For serum glucose levels, we
referred to American Diabetes Association (ADA) guidelines
[10]. Subjects with fasting blood glucose >100md/dL were
considered as having impaired blood glucose levels. For
Lp(a) and hsCRP kit ranges were referred. For apolipopro-
teins A1 and B, we referred to IMMAGE instrument cutoﬀ
ranges. Obesity guidelines based on Western populations
markedly underestimate the risk among all Asians because
Asians have greater body fat at a given BMI [11]( Table 2).
For BMI and abdominal obesity cutoﬀ ranges, we referred
to consensus guidelines for Asian Indians. Prevalence of
metabolic syndrome in the cohort was assessed on the basis
of the following criteria: the 2001 modiﬁed NCEP-ATP III-
2 guidelines, wherein presence of any three of the following
traits in the same individual would meet the criteria for MS:Cholesterol 3
Table 2: Reference ranges.
(a) Lipid proﬁle
Normal (mmol/L) High (mmol/L)
Cholesterol (TC) <5.18 ≥5.18
Triglycerides (TG) <1.69 ≥1.69
Normal (mmol/L) Low (mmol/L)
HDL-C ≥1.03 <1.03
(b) Cardiac markers ranges
Normal High
Lp(a) ≤1.07µmol/L >1.07µmol/L
hsCRP ≤0.75mg/dL >0.75mg/dL
APOB-MALES <1.62g/L ≥1.62g/L
APOB-FEMALES <1.71g/L ≥1.71g/L
Normal Low
APOA-MALES ≥0.90g/L <0.90g/L
APOA-FEMALES ≥1.07g/L <1.07g/L
APOA/APOB ratio ≤1 >1
(c) Glucose levels
Normal (mmol/L) High ((mmol/L)
FBS <5.55 ≥5.55
(d) Body mass index
Normal (kg/m2)O v e r w e i g h t ( k g / m 2)O B E S E ( k g / m 2)
BMI 18.5–22.9 23–24.9
￿25
(1) abdominal obesity Men-≥90cm, Women-≥80cm,
(2) serum TG>1.69mmol/L,
(3) HDL-C<1.03mmol/L,
(4) fasting blood glucose level >5.55mmol/L,
(5) blood pressure≥130/85mmHg.
2.5. Statistical Analysis. The statistical analysis was per-
formed using Stata (SE 10.1 version). Results were expressed
as mean±standard deviation (SD). Pearson’s chi-square test
was applied to test the relationship of categorised indepen-
dent and dependent variables. Odds ratio and their 95%
conﬁdence intervals were calculated for all 2 × 2t a b l e s .AP
value(signiﬁcance) of <.05is deemedstatistically signiﬁcant.
A signiﬁcance of .000 should be read as P<. 0001 (very
highly signiﬁcant) as the software can detect signiﬁcance up
to 3 decimal points only. Unpaired T-test (gender) and one-
way analysis of variance (age) was performed. If ANOVA
was signiﬁcant, Bonferroni’s t procedure was performed to
assess diﬀerence between pairs. Prevalence of MS by means
of its determinants was calculated using the prevalence rate
formula: number of patients per total number of all subjects
atthetimeofstudymultipliedby100.Resultswereexpressed
as percentages.
Table 3: The general characteristics of the study population.
Characteristics of the study population
Characteristics Males
n (%)
Females
n (%) Total P value
Age (years)
20–40YRS 58 (18.65) 41 (16.02) 99 (17.46)
41–60YRS 149 (47.91) 147 (57.42) 296 (52.20) .075
>60YRS 104 (33.44) 68 (26.56) 172 (30.34)
BMI
Normal 62 (20.53) 53 (21.54) 115 (20.99)
Overweight 147 (48.68) 101 (41.06) 248 (45.26) .169
OBESE 93 (30.79) 92 (37.4) 185 (33.76)
Smoking
Non-smokers 195 (74.14) 243 (96.43) 438 (85.05) <.001∗
Smokers 68 (25.86) 9 (3.57) 77 (14.95)
Alcohol
No alcohol
consumption 235 (75.56) 251 (98.05) 486 (85.71) <.001∗
Alcohol
consumption 76 (24.44) 5 (1.95) 81 (14.29)
HTN
Normal 233 (71.70) 179 (69.92) 402 (70.90) .642
H/O HTN 88 (28.3.) 77 (30.08) 165 (29.10)
Diabetes
Normal 244 (78.46) 221 (86.33) 465 (82.01) .015∗∗
H/O diabetes 67 (21.54) 35 (13.67) 102 (17.99)
(∗-signiﬁcant).
3.Results
A total of ﬁve hundred and forty eight subjects participated
in thestudy. On applyingmodiﬁed NCEPATP III,consensus
guidelines fordeﬁning obesity in Asian Indians and ADA,we
found out that nearly 95% of the subjects had at least one
abnormal parameter. The general characteristics of the study
p o p u l a t i o na r eg i v e ni n( Table 3).
3.1. Demographic Characteristics. The gender distribution
was 56.75% males and 46.71% females. The age of the sub-
jects ranged from 20 to 90 years, with a mean age in males
of 54.28 years (SD=13.89) and in females of 52.67 years
(SD = 12.76). Of these, 18.65% males and 16.02% females
were in 20–40 age group, 47.91% males and 57.42% females
were in 41–60 age group, and 33.44% males and 26.56%
females were >60 years old.
3.2. Anthropometric Proﬁle. Our results showed a mean BMI
of25.68inmalesand 26.95infemaleswith a95% conﬁdence
interval (CI) of (25.27–26.09 in males) and (26.3–27.6
in females), which clearly shows that the prevalence of
BMI≥23kg/m2 was signiﬁcant in females than in males
(P = .008). Both in males and females, the prevalence of
overweight BMI (≥23kg/m2) shows linear increase with age
and was found to be more in males than females. The overall4 Cholesterol
prevalence of BMI (≥23kg/m2) was 79.01%. The prevalence
of obesity was high in 41–60 age group females than 20–40
age group and >60 age group. The prevalence of obesity is
almost the same in 20–40 and 41–60 age group males but
drops down as age advances. The incidence of abdominal
obesity observed was 70.9% and waist to hip ratio was
73.76%.
3.3. Lifestyle or Behavioural Determinants. Our results
showed that around 15% of the participants in the study
were alcoholic and smokers. The prevalence of smokers and
alcoholic was highly signiﬁcant in males, as compared to
females. In males 41–60 age group showed high prevalence
of smokers and alcoholic as compared to 20–40 and >60 age
groups.
3.4. Clinical Analysis. It was found in the current study
that history of hypertension and diabetes increases as age
advances both in males and females. Prevalence of history
of diabetes was signiﬁcant in males than in females (P =
.015). Prevalence of history of hypertension in both males
and females was highly signiﬁcant in 41–60 age groups (P<
.0001). History of diabetes in 41–60 age group males was
highly signiﬁcant (P<. 0001). Prevalence of family history
of cardiovascular diseases was observed in 27.76% subjects.
3.5. Biochemical Analysis
3.5.1. Lipids. Increased fasting blood glucose, hypertriglyc-
eridemia and decreased levels of HDL-C were found to be
more in males with high TG and low HDL-C to be highly
signiﬁcant (P<. 0001). Hypercholesterolemia was highly
signiﬁcant in females as compared to males. Both males and
females in 41–60 age groups showed signiﬁcantly high levels
ofimpairedglucoselevels(P<. 0001).Onfurthercomparing
agewise, prevalence of low HDL-C in 20–40 age group males
was 64.91% which is very high as compared to other age
groupsbothinmalesandfemales.In males,theprevalenceof
hypercholesterolemia, and hypertriglyceridemia was found
to be more in 41–60 age group. In females, fasting blood glu-
cose,hypertriglyceridemiaandhypercholesterolemiashowed
a linear increase with age.
3.5.2. Cardiac Markers. Percentage prevalence of APO B and
APO B/APO A1 ratio was found to be more in males than
females. Prevalence of APO A1 was approximately similar
in males and females. High levels Lp(a) and hsCRP was
seen in females than in males. In females, Lp(a) and hsCRP
prevalence was seen more in young adults (20–40age group)
than the other two groups under study.
3.6. Metabolic Syndrome. The overall prevalence of MS
having ≥3 components was 19.52% by modiﬁed NCEP
ATP III criteria. The prevalence of MS in males was
almost double (25.16%) than females (12.6%), and this was
highly signiﬁcant (P = .008). The agewise distribution of
prevalence ofMS was found to be the same in 20–40and 41–
60 age groups (20.61% and 20.76%), respectively, whereas
>60 age group showed a marginal decrease in the prevalence
(16.66%).The prevalence of individual components of MS is
reported in (Figure 1).
3.7. Prevalence of Risk Factors of ASCVD. The prevalence
of major risk factors of ASCVD was 45.25% overweight,
33.75% obese, 39.96% having impaired blood glucose levels,
39.96% subjects with hypercholesterolemia, 38.13% with
hypertriglyceridemia, and 47.97% with low HDL-C. The
prevalence of elevated cardiac markers was 2.18% with
high APO B, 1.82% with increased APO A, 30.65% and
8.39% with elevated levels of Lp(a) and hsCRP, respectively
(Figure 2).
4.Disscussion
Asian Indians are a high risk population with respect to
diabetes and CVD, and the numbers are consistently on
the rise [12]. The prevalence of MS in Asian Indians varies
according to the region, the extent of urbanization, lifestyle
patterns, and socioeconomic/cultural factors. Recent data
show that about one third of the urban population in
India’s major cities have MS [13]. The NCEP deﬁnition is
more ﬂexible as it can diagnose MS even in the absence
of glucose intolerance, which in itself is a predisposition to
dysmetabolic dyslipidemia, an obesity phenotype and proin-
ﬂammatory status. The prevalence of MS by modiﬁed NCEP
ATP III criteria in the current study showed gender-speciﬁc
diﬀerences.Ourresultsillustratemarkedheterogeneityinthe
prevalence of MS according to gender. The prevalence of MS
in our study in males was 2 times higher as compared to
females, whereas in other studies in India, MS prevalence
in women was 1.5–2 times higher than in males [14, 15].
A higher prevalence in men might be related to their higher
rates of overweight BMI, impaired blood glucose levels, high
TG, and low levels of HDL-C.
Chow et al. [16] found a prevalence of MS of 26.9% in
males and 18.4% in females in southern India which is in
concordance with our results. We found the prevalence of
MSinourstudypopulationtobe19.52%,which corroborate
withDeepaetal.[17]CURES34studyshowingprevalenceof
18.3%. The prevalence of MS did not change with respect to
age diﬀerence, 20–40 and 41–60 age groups showed similar
prevalence of MS, and a marginal decrease was seen in >60
age group.
The development of obesity, or more speciﬁcally an in-
crease in abdominal fat, is thought tobe the primary eventin
the progression of MS. A tendency to gain fat in the abdom-
inal area, as opposed to the hip, buttock, and limb areas, is
linked to a rise in fatty acids in the blood, which is thought
to lead to insulin resistance, high blood pressure, abdominal
blood lipids, and eventually diabetes. Asian Indians tend
to develop central obesity rather than generalised obesity.
About three fourth of the subjects participated in study
were overweight/obese (BMI ≥ 23kg/m2), being a prime
determinant of MS prevalence. Of these around one third
of overweight/obese subjects had impaired glucose tolerance
and many exhibit features of MS.Cholesterol 5
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Figure 1: Age- and gender-speciﬁc prevalence of individual components of MS.
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Figure 2: Gender-speciﬁc prevalence of diﬀerent atherosclerotic risk factors.
In our study, we observed approximately 15% of subjects
had history of diabetes. This means that the remaining
subjects with impaired blood glucose levels that is, 25% of
subjects were on their way to develop diabetes, which is an
important risk factor for CAD. Enas et al. [18] in Coronary
ArteryDiseaseinIndians(CADI)studyreport theprevalence
of diabetes to be 3–6 times higher among South Asians
than Europeans, Americans, and other Asians. In India, it is
estimatedthat32millionpeoplesuﬀerfromdiabetes,andthe
number is projected to increase to 69.8 million by 2025 [12].
Increased prevalence of low HDL-C has been reported
earlier by Enas et al. [18] who found that only 4% of
Asian Indian men and 5% Asian Indian women had optimal
HDL-C levels. Low HDL-C levels are a strong predictor of
occurrence and reoccurrence of Myocardial infract (MI) and
stroke and are associated with premature and severe CAD.
Approximatelyhalf of the population had low levelsofHDL-
C ofwhich 65%were males from20–40age groupthat is, the
young adults. Similar ﬁndings were also reported by Sawant
et al. [19] a recent study on 9000 subjects (<40 years of
age) attending the Health Check program at P. D. Hinduja
National Hospital, it was shown that around 64.2% men
and 33.8% women had abnormally low levels of HDL-C.
Obesity reduces HDL-C levels, and obese patients with MS
and atherogenic dyslipidemia almost always have low HDL-
C levels. Our study shows that around 35% of subjects had
low HDL-C were either overweight or obese.
The novel aspect of this study is that along with clinical
and biochemical features of MS, prevalence of risk factors
for ASCVD with cardiac markers was systematically assessed.
Along with traditional risk factors, emerging factors present
in the South Asian population are allowing for further CAD6 Cholesterol
risk stratiﬁcation. At the forefront is APOB/APO A1 ratio.
APOB is the major apolipoprotein found in low density
lipoprotein (LDL), Intermediate-density lipoprotein (IDL),
and very low density lipoprotein (VLDL), and it is the
primary ligand for the LDL receptor. APO A1 is the major
protein constituent of HDL. The APO B/APO A1 ratio
provides an atherogenic to antiatherogenic lipoprotein ratio
that has been shown to be a better predictor of CVD than
LDL level and HDL level. The APO B/APO A1 ratio can
identify individuals with preponderance of small dense LDL
particles[8].In ourstudy, 15.76%males and 11.33% females
were found to have abnormal APO B/APO A1 ratio.
Lipoproteina(Lp(a)),consideredanemergingriskfactor
by NCEP ATP III, has been implicated in the developmentof
the premature atherosclerotic disease seen in South Asians
[8]. Among patients with Lp(a) excess, the CAD risk is
increased by 3-fold in the absence of other risk factors.
The risk increases to eightfold with low HDL-C, 12-fold
with high LDL-C, 16-fold with diabetes and 25-fold with
TC/HDL-C ratio. The higher the Lp(a) level the lower the
age of ﬁrst heart attack, and the most aﬀected individuals
develop MI by the third to ﬁfth decade of life. High levels
of Lp(a) correlate with the prematurity, severity, extent,
and progression of coronary atherosclerosis as well as the
occurrence and recurrence of MI among Asian Indians [12].
In our study, 26.37% of males and 33.73% females showed
elevated levels of Lp(a).
The cardiovascular ﬁeld has recently shown great interest
in the role of inﬂammation in the development of ASCVD.
The basic concept is that atherogenesis represents a state
of chronic inﬂammation. The ﬁndings that elevations of
serum CRP carry predictive power for the development of
major cardiovascular events led to the conceptthat advanced
and unstable atherosclerotic plaques are in an even higher
state of inﬂammation than stable plaques. In our study,
females (10.2%)had higher rates ofelevated CRP than males
(6.43%). It is of interest that obese persons and particularly
those with metabolic syndrome also have elevated levels of
CRP[20].Itwasfoundthatofthetotalsubjectswithelevated
CRP 86.95% were found to be obese.
The prevalence of MS in the present study is much lower
than that reported in an earlier study in urban Indian adults
aged (20–50 years) in which the prevalence was reported
to be 41.1% [21]. The prevalence of MS based on ATP
III criteria in Jaipur (urban north Indian population) was
24.9%. In Chennai urban population Study (CUPS) [22],
the prevalence of MS as deﬁned by EGIR was found to be
11.2%. In the study of 10 industrial settings, prevalence of
MS was 26.6% [3]. Among Asian Indian, Immigrants living
inUSshowedtheprevalenceofMStobe32%.Theseﬁndings
suggest that there is a signiﬁcant diﬀerence even within an
urban environment in diﬀerent socioeconomic groups.
The high levels of risk observed with our baseline
cross-sectional survey justify the need for establishing a
surveillance system to monitor the trends of MS and ASCVD
risk factors over time. Continuing surveillance eﬀorts would
provide us with an opportunity to develop evidence-based
cost-eﬀective CVD prevention, detection, and manage-
ment strategies. Early intervention particularly with lifestyle
change would delay the onset of advance forms of MS and a
high-risk status. Regular physical activity, lifetime abstinence
of tobacco, avoidance in the consumption of trans fats (fried
food), and reduced intake of saturated fats together with an
increased intake of fruits and vegetables form the foundation
of lifestyle changes. Adopting a healthy lifestyle beginning
in childhood and adolescence is warranted in view of the
malignant nature of CAD among Asian Indians [12, 23].
5.Conclusion
Clinical diabetes and CAD are preceded by a constellation of
risk factors that are also the components of MS. In conclu-
sion,prevalenceofMSvaries amongst ethnicgroups.Indians
arehighatriskforCVDandtheirpredispositions.Thepreva-
lence of MS was double in males as compared to females.
This study revealed the increased prevalence of MS to be
more prevalent in 41–60 years, suggesting that this group is
at increased risk of developing CAD. It was also found that
high percentage prevalence of overweight and obesity was
one of the major driving forces in the development of MS.
Therefore,early identiﬁcationofthemetabolicabnormalities
and appropriate intervention may be of primary importance
in populations especially like ours having high prevalence.
6.Limitation
Duetomissing/unavailabilityofbloodpressuredata,wewere
not able to include it in the present study, but would try to
incorporate it later when we obtain complete information
on the same. As cluster of three or more, risk factors can be
termed as metabolic syndrome, in the current study as per
NCEP ATP III guidelines abdominal obesity, HDL-C levels,
triglyceridelevels,andfasting bloodglucoselevelswere taken
into consideration.
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